Did you miss IACA Dinner meeting at ASCO 2017? See highlights below;
Come join us at our Annual Dinner Meeting at ASCO 2017 to honor two deserving oncologist and take part in hearing their incredible stories.
When: Saturday, June 3 at 6:15pm
Where: The Westin Michigan Avenue – Chicago Ballroom
909 North Michigan Avenue, Chicago, IL 60611
While you are at ASCO 2017, also come visit us at our Booth #5035 in the Exhibit Hall.
Applications for IACA’s John N. Kapoor Traveling Fellowship are being accepted through the Traveling Fellowship online portal.
IACA’s John N. Kapoor Traveling Fellowship is dedicated to improving cancer care in the Indian subcontinent by training cancer specialists from the subcontinent at renowned institutions in the United States.
The Fellowship is open to practicing cancer specialists who are interested in mastering specific skills to improve their work at major government or nonprofit hospitals in the Indian subcontinent. Candidates are selected based on their individual qualifications, recommendation letters from their home institution, and commitment to gaining valuable training for the purpose of practical utilization. Preference is given to candidates whose institutions champion low cost or free medical services to underserved populations and also provide teaching and training to postgraduate doctors.
Please visit travelingfellowship.org for more information and to register.
If you have additional questions, please email TF@iacaweb.org.
IACA Annual Meeting at ASCO 2017 – IACA Award for Outstanding Contributions to Oncology & Keynote Speaker
While you are at ASCO 2017, also come visit us at our Booth #5035 in the Exhibit Hall
Impact of STAT3 Mutations on Clinical Features and Treatment Outcomes in Large Granular Lymphocyte Leukemia
Efficacy and Bleeding Risk of Newer Anticoagulants Compared to Conventional Treatment in Patients with Chronic Kidney Disease- a Meta-Analysis of Randomized Controlled Trials
Platelet Activation and Aggregation in Patients with Advanced Adenocarcinoma Undergoing Chemotherapy: Correlation with a Validated Venous Thromboembolism Risk Score
Augmenting Neutrophil Function By Administration of Peg-Filgrastim Potentiates Rituximab and Is Safe in Patients with Indolent B-Cell Non-Hodgkin Lymphomas: Results of a Phase II Study